《骨髓增生异常综合征/肿瘤(MDS)的分类、风险分层和治疗效果评估: 国际MDS联盟(icMDS)最新报告》
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
发表日期：2023 Aug 19
作者：
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel T Starczynowski, Mikkael A Sekeres, Guillermo Sanz, David A Sallman, Gail J Roboz, Uwe Platzbecker, Mrinal M Patnaik, Eric Padron, Olatoyosi Odenike, Stephen D Nimer, Aziz Nazha, Ravi Majeti, Sanam Loghavi, Richard F Little, Alan F List, Tae Kon Kim, Christopher S Hourigan, Robert P Hasserjian, Stephanie Halene, Elizabeth A Griffiths, Steven D Gore, Peter Greenberg, Maria E Figueroa, Pierre Fenaux, Fabio Efficace, Amy E DeZern, Naval G Daver, Jane E Churpek, Hetty E Carraway, Rena Buckstein, Andrew M Brunner, Jacqueline Boultwood, Uma Borate, Rafael Bejar, John M Bennett, Andrew H Wei, Valeria Santini, Michael R Savona, Amer M Zeidan
来源：
BIOMEDICINE & PHARMACOTHERAPY
摘要：
近期，关于骨髓增生异常综合症/肿瘤（MDS）的分类、预后评估和治疗反应评估的指南都已经更新。在国际MDS联盟（icMDS）的报告中，我们总结了这些进展。我们首先对世界卫生组织（WHO）的最新分类和国际共识分类（ICC）进行了批判性审视。然后，我们比较了传统和基于分子的MDS风险评估工具。最后，我们讨论了评估治疗效益的标准的局限性，并强调了国际工作组（IWG）2018年和2023年反应标准如何解决这些缺陷，并得到icMDS的支持。我们还讨论了以患者为中心的护理的重要性，通过讨论生活质量评估的价值。我们希望本综述的读者能够更好地理解如何对MDS进行分类、预测临床预后和评估治疗效果。版权所有©2023 Elsevier Ltd. 保留所有权利。
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.Copyright © 2023 Elsevier Ltd. All rights reserved.